Form 4: Boston Scientific Exec Sells Shares After Option Exercise

Joseph Michael Fitzgerald, EVP & Group President of Cardiology at Boston Scientific, exercised options and subsequently sold a portion of his common stock holdings.

Summary

• Joseph Michael Fitzgerald, EVP & Group President of Cardiology at Boston Scientific Corp (BSX), engaged in transactions on November 3, 2025.
• Exercised options to acquire 50,000 shares of Common Stock at an exercise price of $26.15 per share.
• Sold a total of 50,000 shares of Common Stock in multiple transactions on the same day.
• The sales occurred at weighted average prices of $100.7481 (3,600 shares), $99.7607 (16,928 shares), and $99.1414 (29,472 shares).
• All reported transactions were executed pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 27, 2025.
• Direct beneficial ownership of Common Stock decreased from 228,342 shares to 178,342 shares following these transactions.
• Indirect beneficial ownership of 5,234 shares held by a child is reported, but the reporting person disclaims beneficial ownership of these shares.

Sentiment

Score: 5

Explanation: The executive exercised options and immediately sold the acquired shares, a common practice for liquidity and diversification, especially when executed under a 10b5-1 plan. While it represents a reduction in direct holdings, it's not necessarily a negative signal about the company's future prospects.

Positives

• The executive realized significant value by exercising stock options at $26.15 and selling shares at prices ranging from $98.57 to $100.80.
• The transactions were conducted under a Rule 10b5-1 trading plan, indicating a pre-planned and systematic approach to managing equity holdings.

Negatives

• The executive's direct beneficial ownership of common stock decreased by 50,000 shares, representing a net reduction in direct holdings.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• The reporting person disclaims beneficial ownership of 5,234 shares held by his child.

Stakeholder Impact

• Shareholders may observe a reduction in direct insider holdings, which could be interpreted differently depending on individual investment philosophies.
• The transactions were pre-planned under a Rule 10b5-1 plan, which aims to mitigate concerns about opportunistic insider trading.

Key Dates

Recommendation

This Form 4 details a routine insider transaction involving option exercise and subsequent sale under a pre-established 10b5-1 plan. While it results in a net reduction of direct insider holdings, it's a common practice for executives to diversify or realize gains from vested options. This filing alone does not provide sufficient information to warrant a 'buy' or 'sell' recommendation, as it doesn't reflect fundamental changes in the company's operations or outlook. Investors should consider broader company performance and market conditions.

Keywords

Boston Scientific, BSX, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Joseph Michael Fitzgerald, Executive Compensation, Rule 10b5-1, Cardiology